Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Enterprise Value (2016 - 2025)

Editas Medicine (EDIT) has disclosed Enterprise Value for 11 consecutive years, with -$165.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 37.51% to -$165.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$165.6 million, a 37.51% increase, with the full-year FY2024 number at -$269.9 million, up 16.46% from a year prior.
  • Enterprise Value was -$165.6 million for Q3 2025 at Editas Medicine, up from -$178.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$165.6 million in Q3 2025 to a low of -$625.3 million in Q1 2021.
  • A 5-year average of -$373.5 million and a median of -$344.3 million in 2022 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: crashed 50.69% in 2021, then skyrocketed 37.51% in 2025.
  • Editas Medicine's Enterprise Value stood at -$499.8 million in 2021, then skyrocketed by 31.12% to -$344.3 million in 2022, then increased by 6.15% to -$323.1 million in 2023, then rose by 16.46% to -$269.9 million in 2024, then skyrocketed by 38.63% to -$165.6 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Enterprise Value are -$165.6 million (Q3 2025), -$178.5 million (Q2 2025), and -$221.0 million (Q1 2025).